Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04745949 · ClinicalTrials.gov registry record · Phase 2
PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy
A Phase 2 study of Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma and Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT04745949 is a Phase 2 study of Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma and Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 31 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04745949, a Phase 2 study of Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma and Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies the effect of brentuximab vedotin and nivolumab alone and in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone in treating patients with untreated, stage I-IV primary mediastinal large B-cell lymphoma. Brentuximab vedotin is a monoclonal antibody, called brentuximab, linked to a toxic agent, called vedotin. Brentuximab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD30 receptors, and delivers vedotin to kill them. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Rituximab is a type of antibody therapy, which targets and attaches to the CD20 protein found on the surface of blood cells with cancer and some healthy blood cells. Chemotherapy drugs, such as cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, or by stopping them from dividing. Prednisone is a steroid, a hormone (chemical messengers) with multiple roles, notably in the immune system and inflammation reduction. Steroids are poisonous to lymphocytes (white blood cells from which lymphomas develop). Giving brentuximab vedotin and nivolumab in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone may help to control the disease and be a less harmful regimen than standard chemotherapy in patients with primary mediastinal large B-cell lymphoma.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Prednisone
- BIOLOGICAL Nivolumab
- DRUG Brentuximab Vedotin
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2021-05-10 |
| Est. Completion | 2027-08-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04745949
The ClinicalTrials.gov registry entry for NCT04745949 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT04745949 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04745949 about?
NCT04745949 is a clinical study titled "PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy". This phase II trial studies the effect of brentuximab vedotin and nivolumab alone and in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone in treating patients with untreated, stage I-IV primary mediastinal large B-cell lymphoma. Brentuximab vedotin is a monoclonal antibody, ...
What is the current status of trial NCT04745949?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2021-05-10. Estimated completion is 2027-08-03.
What conditions does trial NCT04745949 study?
This clinical trial studies the following conditions: Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma.
What interventions are being tested in trial NCT04745949?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Prednisone (DRUG), Nivolumab (BIOLOGICAL), Brentuximab Vedotin (DRUG).
Who is sponsoring clinical trial NCT04745949?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04745949 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma
All registered trials for this condition
Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.